Pregnancy, Policy, and Painkillers

Recently, the White House and the FDA issued statements suggesting a possible connection between prenatal acetaminophen exposure and increased risks of autism and ADHD. These announcements have prompted strong reactions from the scientific community. Organizations like The American College of Obstetricians and Gynecologists and The World Health Organization have responded with caution, emphasizing that the current evidence does not support a definitive causal link.

So, what does the science actually say?

Read the full article

• Autism and Acetaminophen Use during Pregnancy: Does Science Support the Claim of a Link?

About the author

• Matt Quinn, Ph.D.

Transcript

Welcome to Womble Perspectives, where we explore a wide range of topics, from the latest legal updates to industry trends to the business of law. Our team of lawyers, professionals and occasional outside guests will take you through the most pressing issues facing businesses today and provide practical and actionable advice to help you navigate the ever changing legal landscape.

With a focus on innovation, collaboration and client service. We are committed to delivering exceptional value to our clients and to the communities we serve. And now our latest episode.

Welcome back to Womble Perspectives. Today, we’re diving into a topic that’s sparked concern and controversy: the potential link between acetaminophen use during pregnancy and neurodevelopmental disorders in children.

Recently, the White House and the FDA issued statements suggesting a possible connection between prenatal acetaminophen exposure and increased risks of autism and ADHD. These announcements have prompted strong reactions from the scientific community. Organizations like The American College of Obstetricians and Gynecologists and The World Health Organization have responded with caution, emphasizing that the current evidence does not support a definitive causal link.

So, what does the science actually say?

The investigation into this potential association began back in the 1980s. Since then, researchers have conducted dozens of studies, with mixed results. A recent comprehensive analysis by Prada and colleagues reviewed 46 studies on the topic. Of those, 27 reported a positive association between acetaminophen use during pregnancy and neurodevelopmental disorders, 9 found no significant link, and 4 even suggested a protective effect.

The takeaway? There’s evidence that points to a possible association—but it’s far from conclusive. The Prada study emphasized the wide variation in study design, populations, and methodologies, which made it impossible to conduct a quantitative synthesis. Instead, they opted for a qualitative review, highlighting the need for more consistent and rigorous research.

On the other side of the debate, a large-scale study by Ahlqvist et al. in Sweden examined nearly 2.5 million children. Initially, their models showed a slight increase in risk for autism, ADHD, and intellectual disability among children whose mothers used acetaminophen during pregnancy. But here’s where it gets interesting: when they conducted sibling control analyses—comparing exposed children to their unexposed siblings—the association disappeared.

This suggests that shared genetic or environmental factors, rather than acetaminophen itself, may be responsible for the increased risk. The study also found no dose-response pattern, which further weakens the argument for a causal link. Additionally, maternal characteristics like lower socioeconomic status, higher BMI, and psychiatric history were associated with both increased acetaminophen use and higher risk of neurodevelopmental disorders.

One of the biggest challenges in this field is what researchers call “confounding by indication.” In simple terms, mothers take acetaminophen to treat infections, fevers, and pain—conditions that themselves may increase the risk of neurodevelopmental issues in children. So, is it the medication or the underlying condition that’s driving the risk? That question remains unanswered.

Another limitation is the reliance on self-reported data. Most studies don’t have formal documentation of dosage, timing, or duration of acetaminophen use. This lack of precision makes it difficult to draw firm conclusions and contributes to the variability in findings.

So, where do we go from here?

While some evidence suggests a potential link, the lack of definitive causal proof and the presence of numerous confounding factors mean we need to interpret these findings with caution. More rigorous, controlled studies are needed to clarify the relationship and explore possible mechanisms.

In the meantime, the World Health Organization advises pregnant women to consult their healthcare providers and use medications cautiously—especially during the first trimester.

As policies progress, we’ll continue to follow developments in this area and bring you updates on other key scientific topics that impact public health.

Thank you for listening to Womble Perspectives. If you want to learn more about the topics discussed in this episode, please visit The Show Notes, where you can find links to related resources mentioned today. The Show Notes also have more information about our attorneys who provided today's insights, including ways to reach out to them.

Don't forget to subscribe via your podcast player of choice so that you never miss an episode. Thank you again for listening.